Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 16/20 | 0.56 |
| ▸ | ITGAV | P06756 | 2/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 15/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 13/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312750 | 0.92 | ITGA4 (0.58) | ITGB1ITGAVITGA4ITGB7HDAC1 | |
| SCHEMBL3314241 | 0.88 | ITGB1 (0.70) | ITGB1ITGAVITGA4ITGB7 | |
| SCHEMBL8353596 | 0.84 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7 | |
| SCHEMBL3319924 | 0.84 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7 | |
| SCHEMBL3315770 | 0.84 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7 | |
| SCHEMBL3314549 | 0.84 | ITGB1 (0.61) | ITGB1ITGAVITGA4ITGB7 | |
| SCHEMBL3315332 | 0.81 | ALDH1A1 (0.44) | ITGB1ITGAVHDAC1HDAC6 | |
| SCHEMBL3314284 | 0.81 | TACR1 (0.55) | ITGB1ITGAVITGA4ITGB7HDAC1 | |
| SCHEMBL20025228 | 0.81 | ITGB1 (0.59) | ITGB1ITGAVITGA4ITGB7 | |
| SCHEMBL5781376 | 0.81 | ITGA4 (0.70) | ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | UCB, S.A. (BE) | 2008-03-13 | — | — | US | disclosed |
| EP-1501801-B1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES | UCB PHARMA SA (BE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1870402-A1 | 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors | UCB Pharma, S.A. (BE) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | VCAM1, HRH4, LTA4H | ITGB1 781/4885ITGAV 425/4885ITGA4 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.